Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates
Open Access
- 16 March 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 218 (2) , 218-227
Abstract
The emerging zoonotic paramyxovirus Nipah virus (NiV) causes severe respiratory and neurological disease in humans, with high fatality rates. Nipah virus can be transmitted via person-to-person contact, posing a high risk for epidemic outbreaks. However, a broadly applicable approach for human NiV outbreaks in field settings is lacking. We engineered new antiviral lipopeptides and analyzed in vitro fusion inhibition to identify an optimal candidate for prophylaxis of NiV infection in the lower respiratory tract, and we assessed antiviral efficiency in 2 different animal models. We show that lethal NiV infection can be prevented with lipopeptides delivered via the respiratory route in both hamsters and nonhuman primates. By targeting retention of peptides for NiV prophylaxis in the respiratory tract, we avoid its systemic delivery in individuals who need only prevention, and thus we increase the safety of treatment and enhance utility of the intervention. The experiments provide a proof of concept for the use of antifusion lipopeptides for prophylaxis of lethal NiV. These results advance the goal of rational development of potent lipopeptide inhibitors with desirable pharmacokinetic and biodistribution properties and a safe effective delivery method to target NiV and other pathogenic viruses.Keywords
Funding Information
- National Institutes of Health (RO1AI114736, R33AI101333, RO1AI031971)
- ANR Astrid
- ANR Astrid Maturation
- LABEX ECOFECT (ANR-11-LABX-0048, ANR-11-IDEX-0007)
- French National Research Agency
This publication has 45 references indexed in Scilit:
- Protection from Hendra virus infection with Canarypox recombinant vaccinenpj Vaccines, 2016
- Henipavirus pathogenesis and antiviral approachesExpert Review of Anti-infective Therapy, 2014
- Henipavirus outbreaks to antivirals: the current status of potential therapeuticsCurrent Opinion in Virology, 2012
- Bats host major mammalian paramyxovirusesNature Communications, 2012
- Inhibition of Nipah Virus Infection In Vivo: Targeting an Early Stage of Paramyxovirus Fusion Activation during Viral EntryPLOS Pathogens, 2010
- Experimental Infection of Squirrel Monkeys with Nipah VirusEmerging Infectious Diseases, 2010
- Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor BindingPLOS Pathogens, 2009
- Potent D-peptide inhibitors of HIV-1 entryProceedings of the National Academy of Sciences, 2007
- A Golden Hamster Model for Human Acute Nipah Virus InfectionThe American Journal of Pathology, 2003
- Alpha complementation of LacZ in mammalian cellsNucleic Acids Research, 1996